

**Editor Board of
Trend in
Bio/Pharmaceutical
Industry**

Editor in Chief

John Wang
Novartis, USA

Editors

Chengjun Mo
Medimmune, USA

Daniel Liu
Jonson and Jonson, USA

Deqian Wang
Bayer, USA

Jinzi Wu
*Ambrilia Biopharma Inc.
Canada*

Jun Han
Novartis, USA

Leping Li
Amgen, USA

Li Shi
Merck, USA

Naibo Yang
Molecular Devices, USA

Pei Yang
Nektar, USA

Yingfei Wei
Elixirin, USA

Guest Editor

Ruifang Wu
*Chief Executive Editor
Chinese Journal of
New Drugs, China*

Art Director

Xiaojun Li
CA State, USA

TBI online

www.sapa-west.org

Contact us:

publicatbi@sapa-west.org

Letter from Editor

Dear TBI readers,



First of all, I want to point out that TBI, our Journal, has been growing healthily and quickly. Please look at the editor board list on the left – several new editors from other regions of the USA, from Canada and China, were added. We have grown out the boundary of west coast of United States with more national and international exposure. Such a great achievement is a result of commitment and hard work from many of our editors and our contributors. Let's keep it up!

Secondly, I want to say a few words about the articles in this issue. As usual, we cover a variety of fields in this issue, from patent management to talent management, from cell-based screening method to formulation & drug delivery. The two articles from China, one focused on patent law comparison and the other on strategic talent management, are worthwhile to pay a special attention here because one of our missions is to promote collaborations and communication across the pacific ocean. These two articles clearly reflected the latest changes with rapidly modernized China. I have learned a lot from these two articles myself.

The two articles contributed by Jun Han and Weijun Li, are also very interesting to read. Having been working in the field of pre-clinical formulation and drug delivery for many years, I can not help to share the excitement with you about the new development in this area. Particularly the drug delivery technology is emerging as a distinguishable branch of pharmaceutical sciences, and it is even growing into a truly multi-disciplinary technology. For example, PEGylation of protein therapeutics has recently become a "Protein Engineering" driven technology because protein mutation is necessary in order to link the PEG to a specific site of a protein in order to increase its half-life or stability. From a business point of view, drug delivery can not only be employed prospectively to more efficiently deliver new drug candidates in the development stage, but also retrospectively as a life-cycle-management tool to improve the delivery system for a marketed product. As a result, many start-up companies have formed in this field and it has become a most active filed in pharmaceutical sciences. I wish we will read many more articles in the field of drug delivery in the future.

I really enjoyed my reading of this issue; I am sure you will too!

DQ
Editor